Switch to:
Also traded in: Germany, South Africa

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.24
OTCPK:APNHF's Cash to Debt is ranked lower than
85% of the 778 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.15 vs. OTCPK:APNHF: 0.24 )
Ranked among companies with meaningful Cash to Debt only.
OTCPK:APNHF' s Cash to Debt Range Over the Past 10 Years
Min: 0.22  Med: 0.36 Max: N/A
Current: 0.24
Equity to Asset 0.41
OTCPK:APNHF's Equity to Asset is ranked lower than
79% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. OTCPK:APNHF: 0.41 )
Ranked among companies with meaningful Equity to Asset only.
OTCPK:APNHF' s Equity to Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.5 Max: 0.55
Current: 0.41
0.31
0.55
Interest Coverage 4.87
OTCPK:APNHF's Interest Coverage is ranked lower than
81% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.32 vs. OTCPK:APNHF: 4.87 )
Ranked among companies with meaningful Interest Coverage only.
OTCPK:APNHF' s Interest Coverage Range Over the Past 10 Years
Min: 3.11  Med: 5.14 Max: 7.87
Current: 4.87
3.11
7.87
F-Score: 4
Z-Score: 2.89
M-Score: -2.29
WACC vs ROIC
10.48%
11.77%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 28.70
OTCPK:APNHF's Operating margin (%) is ranked higher than
91% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.44 vs. OTCPK:APNHF: 28.70 )
Ranked among companies with meaningful Operating margin (%) only.
OTCPK:APNHF' s Operating margin (%) Range Over the Past 10 Years
Min: 23.39  Med: 25.8 Max: 28.7
Current: 28.7
23.39
28.7
Net-margin (%) 17.02
OTCPK:APNHF's Net-margin (%) is ranked higher than
83% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. OTCPK:APNHF: 17.02 )
Ranked among companies with meaningful Net-margin (%) only.
OTCPK:APNHF' s Net-margin (%) Range Over the Past 10 Years
Min: 14.4  Med: 18.35 Max: 20.82
Current: 17.02
14.4
20.82
ROE (%) 16.82
OTCPK:APNHF's ROE (%) is ranked higher than
78% of the 753 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.76 vs. OTCPK:APNHF: 16.82 )
Ranked among companies with meaningful ROE (%) only.
OTCPK:APNHF' s ROE (%) Range Over the Past 10 Years
Min: 16.51  Med: 24.04 Max: 38.57
Current: 16.82
16.51
38.57
ROA (%) 6.50
OTCPK:APNHF's ROA (%) is ranked higher than
66% of the 783 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. OTCPK:APNHF: 6.50 )
Ranked among companies with meaningful ROA (%) only.
OTCPK:APNHF' s ROA (%) Range Over the Past 10 Years
Min: 6.08  Med: 10.35 Max: 17.19
Current: 6.5
6.08
17.19
ROC (Joel Greenblatt) (%) 43.79
OTCPK:APNHF's ROC (Joel Greenblatt) (%) is ranked higher than
81% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.07 vs. OTCPK:APNHF: 43.79 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OTCPK:APNHF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 37.42  Med: 68.71 Max: 164.05
Current: 43.79
37.42
164.05
Revenue Growth (3Y)(%) 33.20
OTCPK:APNHF's Revenue Growth (3Y)(%) is ranked higher than
91% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.60 vs. OTCPK:APNHF: 33.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OTCPK:APNHF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 15  Med: 25.5 Max: 33.4
Current: 33.2
15
33.4
EBITDA Growth (3Y)(%) 34.30
OTCPK:APNHF's EBITDA Growth (3Y)(%) is ranked higher than
84% of the 564 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.30 vs. OTCPK:APNHF: 34.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OTCPK:APNHF' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 29.1 Max: 46.5
Current: 34.3
0
46.5
EPS Growth (3Y)(%) 24.70
OTCPK:APNHF's EPS Growth (3Y)(%) is ranked higher than
75% of the 529 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.70 vs. OTCPK:APNHF: 24.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OTCPK:APNHF' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 17.9  Med: 26.6 Max: 365.5
Current: 24.7
17.9
365.5
» OTCPK:APNHF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with APNHF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:OTCPK:MTZPY, NYSE:PRGO, OTCPK:MKGAY, NYSE:VRX, OTCPK:SGIOY, OTCPK:ESALY, NYSE:MNK, NYSE:RDY, OTCPK:MDABY, OTCPK:HKMPF, OTCPK:SFOSF, OTCPK:HLUYY, NAS:OPK, OTCPK:HYPMY, OTCPK:IPSEY, NAS:ENDP, NYSE:TARO, NAS:NBIX, NAS:AKRX, NYSE:CTLT » details
Traded in other countries:LDZA.Germany, APN.South Africa,
Aspen Pharmacare Holdings Ltd through its subsidiaries, is engaged in manufacturing, marketing and distribution of branded and generic pharmaceutical, as well as nutritional products.

Aspen Pharmacare Holdings Ltd is a pharmaceutical company. The Company, through its subsidiaries, is engaged in the manufacture, marketing and distribution of branded and generic pharmaceutical, as well as consumer, OTC and nutritional products in selected territories, operating primarily in the healthcare industry. Its product types includes tablets, capsules, eye drops, injectable products (including lyophilized vials), oral contraceptives, form-filled seals, suppositories, liquids, creams, ointments, infant nutritional products, and specialist active pharmaceutical ingredients. The Company operates in South Africa, Australia, Hong Kong, Malaysia, Philippines, Taiwan, Japan, Kenya, Nigeria, Tanzania, Uganda, Ireland, United Arab Emirates, France, Germany, the Netherlands, Mauritius, Brazil, Mexico, Venezuela and the United States of America.

Ratios

vs
industry
vs
history
P/E(ttm) 24.27
APNHF's P/E(ttm) is ranked higher than
60% of the 538 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.52 vs. APNHF: 24.27 )
Ranked among companies with meaningful P/E(ttm) only.
APNHF' s P/E(ttm) Range Over the Past 10 Years
Min: 12.7  Med: 20.26 Max: 39.98
Current: 24.27
12.7
39.98
PE(NRI) 24.25
APNHF's PE(NRI) is ranked higher than
59% of the 537 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.50 vs. APNHF: 24.25 )
Ranked among companies with meaningful PE(NRI) only.
APNHF' s PE(NRI) Range Over the Past 10 Years
Min: 12.99  Med: 21.75 Max: 39.98
Current: 24.25
12.99
39.98
Price/Owner Earnings (ttm) 47.31
APNHF's Price/Owner Earnings (ttm) is ranked lower than
61% of the 276 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.08 vs. APNHF: 47.31 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
APNHF' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 20.7  Med: 47.31 Max: 132.77
Current: 47.31
20.7
132.77
P/B 3.40
APNHF's P/B is ranked lower than
56% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. APNHF: 3.40 )
Ranked among companies with meaningful P/B only.
APNHF' s P/B Range Over the Past 10 Years
Min: 2.66  Med: 4.64 Max: 8.41
Current: 3.4
2.66
8.41
P/S 4.07
APNHF's P/S is ranked lower than
62% of the 695 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. APNHF: 4.07 )
Ranked among companies with meaningful P/S only.
APNHF' s P/S Range Over the Past 10 Years
Min: 2.27  Med: 3.83 Max: 6.78
Current: 4.07
2.27
6.78
PFCF 60.70
APNHF's PFCF is ranked lower than
80% of the 193 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.56 vs. APNHF: 60.70 )
Ranked among companies with meaningful PFCF only.
APNHF' s PFCF Range Over the Past 10 Years
Min: 22.73  Med: 70.1 Max: 341.82
Current: 60.7
22.73
341.82
POCF 30.37
APNHF's POCF is ranked lower than
72% of the 256 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.62 vs. APNHF: 30.37 )
Ranked among companies with meaningful POCF only.
APNHF' s POCF Range Over the Past 10 Years
Min: 14.81  Med: 24.35 Max: 52.18
Current: 30.37
14.81
52.18
EV-to-EBIT 21.16
APNHF's EV-to-EBIT is ranked higher than
50% of the 529 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.31 vs. APNHF: 21.16 )
Ranked among companies with meaningful EV-to-EBIT only.
APNHF' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.8  Med: 15.1 Max: 29.6
Current: 21.16
6.8
29.6
EV-to-EBITDA 18.86
APNHF's EV-to-EBITDA is ranked lower than
54% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.21 vs. APNHF: 18.86 )
Ranked among companies with meaningful EV-to-EBITDA only.
APNHF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.8  Med: 14.5 Max: 28.1
Current: 18.86
6.8
28.1
PEG 1.00
APNHF's PEG is ranked higher than
74% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.14 vs. APNHF: 1.00 )
Ranked among companies with meaningful PEG only.
APNHF' s PEG Range Over the Past 10 Years
Min: 0.37  Med: 0.94 Max: 2.28
Current: 1
0.37
2.28
Shiller P/E 54.68
APNHF's Shiller P/E is ranked lower than
55% of the 159 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.59 vs. APNHF: 54.68 )
Ranked among companies with meaningful Shiller P/E only.
APNHF' s Shiller P/E Range Over the Past 10 Years
Min: 42.62  Med: 63.97 Max: 91.22
Current: 54.68
42.62
91.22
Current Ratio 0.89
APNHF's Current Ratio is ranked lower than
91% of the 678 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.47 vs. APNHF: 0.89 )
Ranked among companies with meaningful Current Ratio only.
APNHF' s Current Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.35 Max: 1.95
Current: 0.89
0.7
1.95
Quick Ratio 0.56
APNHF's Quick Ratio is ranked lower than
93% of the 678 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. APNHF: 0.56 )
Ranked among companies with meaningful Quick Ratio only.
APNHF' s Quick Ratio Range Over the Past 10 Years
Min: 0.49  Med: 0.97 Max: 1.31
Current: 0.56
0.49
1.31
Days Inventory 231.15
APNHF's Days Inventory is ranked lower than
87% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.00 vs. APNHF: 231.15 )
Ranked among companies with meaningful Days Inventory only.
APNHF' s Days Inventory Range Over the Past 10 Years
Min: 115.22  Med: 134.65 Max: 231.15
Current: 231.15
115.22
231.15

Buy Back

vs
industry
vs
history
Dividend Growth (3y) -100.00
APNHF's Dividend Growth (3y) is ranked lower than
91% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. APNHF: -100.00 )
Ranked among companies with meaningful Dividend Growth (3y) only.
APNHF' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 23.2
Current: -100
0
23.2
3-Year Average Share Buyback Ratio -0.10
APNHF's 3-Year Average Share Buyback Ratio is ranked higher than
81% of the 432 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. APNHF: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
APNHF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7.9  Med: -1.65 Max: 1.7
Current: -0.1
-7.9
1.7

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 3.38
APNHF's Price/Projected FCF is ranked lower than
99.99% of the 287 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.65 vs. APNHF: 3.38 )
Ranked among companies with meaningful Price/Projected FCF only.
APNHF' s Price/Projected FCF Range Over the Past 10 Years
Min: 0  Med: 3.84 Max: 5.84
Current: 3.38
0
5.84
Price/DCF (Earnings Based) 0.85
APNHF's Price/DCF (Earnings Based) is ranked higher than
79% of the 80 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. APNHF: 0.85 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.06
APNHF's Price/Median PS Value is ranked lower than
99.99% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. APNHF: 1.06 )
Ranked among companies with meaningful Price/Median PS Value only.
APNHF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0  Med: 0.88 Max: 1.4
Current: 1.06
0
1.4
Price/Peter Lynch Fair Value 1.13
APNHF's Price/Peter Lynch Fair Value is ranked lower than
99.99% of the 142 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. APNHF: 1.13 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
APNHF' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0  Med: 0.87 Max: 1.81
Current: 1.13
0
1.81
Earnings Yield (Greenblatt) (%) 4.70
APNHF's Earnings Yield (Greenblatt) (%) is ranked higher than
65% of the 752 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. APNHF: 4.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
APNHF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.4  Med: 6.6 Max: 14.8
Current: 4.7
3.4
14.8
Forward Rate of Return (Yacktman) (%) 29.09
APNHF's Forward Rate of Return (Yacktman) (%) is ranked higher than
88% of the 330 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.64 vs. APNHF: 29.09 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
APNHF' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.6  Med: 26.9 Max: 38.7
Current: 29.09
1.6
38.7

More Statistics

Revenue (TTM) (Mil) $2,639
EPS (TTM) $ 0.97
Beta1.75
Short Percentage of Float0.00%
52-Week Range $18.37 - 72.66
Shares Outstanding (Mil)456.06
» More Articles for OTCPK:APNHF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Aspen Sinks to Four-Month Low as Volumes Surge After Glaxo Sells Sep 29 2016
Glaxo Sells Stake in South Africa’s Aspen for $619 Million Sep 28 2016
South Africa's Aspen Pharmacare FY profit drops 23 percent Sep 14 2016
Aspen Pharmacare moves into China as South Africa sales dip Sep 14 2016
Aspen Profit Rises as International Operations Boost Drugmaker Sep 14 2016
Aspen Targets Further Chinese Acquisitions After Glaxo Deal Sep 14 2016
GSK sells anaesthetics to Aspen for up to $370 million Sep 12 2016
Aspen to Buy Glaxo Drugs for $372 Million as Deal Spree Goes On Sep 12 2016
GSK sells anaesthetics to Aspen for up to $370 million Sep 12 2016
GSK sells anaesthetics to Aspen for up to $370 million Sep 12 2016
GSK sells anaesthetics to Aspen for up to $370 mln Sep 12 2016
Aspen Tumbles Most in Two Years on Venezuela Loss, Disposals Sep 07 2016
Aspen Says Venezuela Loss, Australia Disposal to Weigh on Profit Sep 07 2016
Aspen Expands in China as African Drugmaker Targets Growth Jul 19 2016
AstraZeneca sells rights to anesthetics for up to $770 million Jun 09 2016
AstraZeneca sells rights to anaesthetics for up to $770 mln Jun 09 2016
Aspen to Buy Anesthetics From AstraZeneca for $520 Million Jun 09 2016
AstraZeneca sells rights to anaesthetics to South Africa's Aspen Jun 09 2016
South Africa's Aspen Pharmacare signs U.S. supply deal with ANI May 18 2016
Starpharma licenses VivaGel BV in Aust, NZ Mar 04 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)